US EditionPublished • loading... • Updated
JCR Pharmaceuticals and Alexion Mark Key Progress in Neurodegenerative Disease Collaboration – Patient Worthy
Summary by Patient Worthy
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
JCR Pharmaceuticals and Alexion Mark Key Progress in Neurodegenerative Disease Collaboration – Patient Worthy
JCR Pharmaceuticals Co., Ltd., a leader in therapies for rare and genetic diseases, has reached an important milestone in its ongoing collaboration with Alexion, AstraZeneca’s rare disease division. The achievement, according to The AI Journal, which triggers a milestone payment from Alexion to JCR, centers on the development of a novel therapeutic protein candidate for […]
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
